BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Crohn's disease clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for Crohn disease: 121 (65 sponsors; 25 newly posted in the last 180 days, 6 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 21.1, rank 26 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 13, Phase 2 29, Phase 3 35, Phase 4 8, N/A 36.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Janssen Research & Development, LLC11P3 8, P4 1, P2 1, NA 110
Takeda TAK14P3 7, P2 3, P4 2, NA 202
AbbVie ABBV14NA 6, P3 6, P2 211
Eli Lilly and Company LLY6P2 2, P3 400
Hoffmann-La Roche4P3 3, P2 101
Janssen-Cilag Ltd.4NA 2, P3 211
Sanofi SNY4P1 1, P2 1, P3 211
Merck Sharp & Dohme LLC MRK2P3 200
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.1P3 101
Agomab Spain S.L.U. new entrant2P1 1, P2 120
AstraZeneca AZN2P2 200
Biocad2P2 1, P1 101
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2P4 210
Direct Biologics, LLC2P2 210
Abivax S.A. ABVX1P2 101
Adacyte Therapeutics SL1NA 100
American Laboratory Products Company AIG1NA 101
Anabio R&D new entrant1NA 110
Anterogen Co., Ltd.1NA 101
AnX Robotica Corp. new entrant1NA 111
Axiom Bioregistry new entrant1NA 110
Benethera (Shaoxing) Biotechnology Co., Ltd. new entrant1P1 111
Biokuris s.a.1NA 100
Celltrion HealthCare France1NA 100
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1P1 100

New-entrant sponsors: Agomab Spain S.L.U., Anabio R&D, AnX Robotica Corp., Axiom Bioregistry, Benethera (Shaoxing) Biotechnology Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Abivax S.A. ABVXNCT06456593 Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's DiseaseModerately to Severely Active Crohn Diseaserecruiting212
2026-12-17 est.P2Sanofi SNYNCT06958536 A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseCrohn's Diseaserecruiting99
2026-12-28 est.P3Jiangsu Topcel-KH Pharmaceutical Co., Ltd.NCT06925594 Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's DiseaseCrohn's Diseaserecruiting228
2026-12-31 est.P2Hoffmann-La RocheNCT05910528 Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's DiseaseCrohns Diseaseactive not recruiting21
2026-12-31 est.P2EL3 Bio, LLC.NCT07010926 A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's DiseaseCrohn&Amp;#39;s; Crohn&Amp;#39;s Disease (CD)not yet recruiting120
2027-02-17 est.P2Takeda TAKNCT06233461 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseCrohn's Diseaserecruiting268

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-12 est.P2Jiangsu Carephar Pharmaceutical Co., Ltd.NCT07677514 A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's DiseaseCrohn's Diseasenot yet recruiting156
2026-09-29P2Sanofi SNYNCT07222189 A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LColitis Ulcerative; Crohn's Diseaseterminated7
2026-08-15 est.P2Telavant, Inc.NCT05471492 Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's DiseaseCrohn Diseasewithdrawn
2026-08-10P2AstraZeneca AZNNCT06681324 Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyCrohn's Diseaseactive not recruiting24
2026-07-30P2Sanofi SNYNCT06637631 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.Crohn's Diseaseterminated105
2026-06-20P2Agomab Spain S.L.U.NCT05843578 STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseaseFibrostenotic Crohn's Diseasecompleted103
2026-06-01 est.P1/P2Intralytix, Inc.NCT03808103 Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's DiseaseCrohn Diseaseactive not recruiting30

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Crohn disease"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.